CF405M Anti-CD19 antibody [A3-B1] (ab117733)
![Flow Cytometry - CF405M Anti-CD19 antibody [A3-B1] (ab117733)](https://www.abcam.com/ps/products/117/ab117733/Images/ab117733-129349-anti-cd19-antibody-a3-b1-cf405m-flow-cytometry.jpg "Flow Cytometry - CF405M Anti-CD19 antibody [A3-B1] (ab117733)")
Key features and details
- CF405M Mouse monoclonal [A3-B1] to CD19
- Suitable for: Flow Cyt
- Reacts with: Human
- Conjugation: CF405M. Ex: 408nm, Em: 452nm
- Isotype: IgG2a
Overview
-
Product name
CF405M Anti-CD19 antibody [A3-B1]
See all CD19 primary antibodies -
Description
CF405M Mouse monoclonal [A3-B1] to CD19 -
Host species
Mouse -
Conjugation
CF405M. Ex: 408nm, Em: 452nm -
Specificity
Directed against the CD19, which is expressed on human B lymphocytes. ab117733 is B lineage-specific and reacts with early B-cell precursors, pre-pre-B-cells, pre-B- cells, B-cells, intermediate B-cells, mature B-cells and some plasmacytoid cells. Plasma cells were found to be negative. It does not react with other haemopoïetic cells. Also reacts with pre-B-cell- lines, B lymphoblastoid cell-lines and Burkitt cell- lines, and with 50% of myeloma cell-lines. Virtually all non T-ALL, B-CLL and B-cell lymphomas were found to be positive, myeloma cells were found to be negative. -
Tested applications
Suitable for: Flow Cytmore details -
Species reactivity
Reacts with: Human -
Immunogen
CD19 antigen which is expressed on human B lymphocytes.
-
Positive control
- Normal Human peripheral blood
-
General notes
CD19 cluster expressed from the earliest stages of B-progenitor development and on all peripheral B cells including germinal centre B cells, all B cell lines tested and B cell leukaemias tested. The antigen is lost on B cell maturation to plasma cells.
Fluorochrome: CF405M (Abs/Em Max: 408/450 nm) CF405M (Abs/Em Max: 408/450nm). Direct replacement for Pacific Blue dye®, BD Horizon™ V450
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. -
Storage buffer
pH: 7.20
Preservatives: 0.09% Sodium azide, 0.028% Proclin 300
Constituent: PBS -
Concentration information loading... -
Purity
Immunogen affinity purified -
Primary antibody notes
CD19 cluster expressed from the earliest stages of B-progenitor development and on all peripheral B cells including germinal centre B cells, all B cell lines tested and B cell leukaemias tested. The antigen is lost on B cell maturation to plasma cells. -
Clonality
Monoclonal -
Clone number
A3-B1 -
Isotype
IgG2a -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab117733 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Flow Cyt | Use 5µl for 106 cells. ab126036 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
|
Target
-
Function
Assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. -
Involvement in disease
Defects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low. -
Sequence similarities
Contains 2 Ig-like C2-type (immunoglobulin-like) domains. -
Post-translational
modificationsPhosphorylated on serine and threonine upon DNA damage, probably by ATM or ATR. Phosphorylated on tyrosine following B-cell activation. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 930 Human
- Omim: 107265 Human
- SwissProt: P15391 Human
- Unigene: 652262 Human
-
Alternative names
- Antibody deficiency due to defect in CD19 antibody
- Antibody deficiency due to defect in CD19, included antibody
- AW495831 antibody
see all
Images
-
Flow Cytometry - CF405M Anti-CD19 antibody [A3-B1] (ab117733)Staining of CD19 using Normal Human peripheral blood with ab117733 (5 µl/106 cells).
-
![Flow Cytometry - CF405M Anti-CD19 antibody [A3-B1] (ab117733)](https://www.abcam.com/ps/products/117/ab117733/Images/ab117733-129348-anti-cd19-antibody-a3-b1-cf405m-flow-cytometry.jpg)
Flow Cytometry - CF405M Anti-CD19 antibody [A3-B1] (ab117733)Staining of CD19 using Normal Human peripheral blood with ab117733 (5 µl/106 cells).
References (0)
ab117733 has not yet been referenced specifically in any publications.
